SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Launched by SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. · Jun 6, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors," is designed to test a new treatment called SSGJ-705 for patients with certain types of advanced cancers. Specifically, it focuses on patients who have tumors that express a protein called HER2, which can be found in cancers like breast cancer, lung cancer, and gastric cancer. The study aims to find out whether SSGJ-705 is safe and effective when used alone or in combination with other treatments.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of locally advanced or metastatic cancer that expresses HER2. They should also be in reasonably good health, meaning they have minimal restrictions on daily activities and are expected to live for more than three months. Participants will need to sign a consent form agreeing to take part in the study. It’s important to note that pregnant or nursing women, individuals with certain medical conditions, or those who have had serious side effects from previous cancer treatments may not be eligible. This trial is currently not recruiting participants, so it will begin enrolling patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males and/or females over age 18.
• • Histologically and/or cytologically documented local advanced or metastatic NSCLC/BC/GC/GEJC.
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• • Expected survival \>3 months.
• • Signed informed consent form.
• Exclusion Criteria:
• • Any remaining AEs \> grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.
• • Pregnant or nursing women or women/men who are ready to give birth.
• • symptomatic central nervous system metastasis.
• • Allergy to other antibody drugs or any excipients in the study drugs.
• • Inadequate organ or bone marrow function.